• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·SUDARSHAN.BO
Share

Sudarshan Pharma Industries Ltd. Stocks

₹ 36.4Last Updated 16.10.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

₹ 95.42M

₹ 36.4
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Sudarshan Pharma Industries Ltd. operates as a supplier of specialty chemicals, intermediates, and active pharmaceutical ingredients. The company strategically sources its products externally to cater to clients both within India and internationally. Additionally, the firm is active in contract manufacturing and provides outsourced generic pharmaceutical formulations and various medicines. These are supplied to a broad spectrum of clients, including healthcare institutions, governmental agencies, non-profit organizations, and hospitals. Established on July 23, 2008, Sudarshan Pharma maintains its corporate headquarters in Mumbai, India.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

17.10.2026 21:12

DeepSeek unveils updated AI model claimed to be faster than its predecessor

17.10.2026 16:01

Small caps last week: Russell 2000 correction, Bumble sale, Crocs celeb partnerships

17.10.2026 13:01

The Weak Link in the AI Revolution: Big Pharma Comes to the Rescue of Investors; Burry Believes in Mortgages

17.10.2026 03:47

‘All of this is going to pass’: Nvidia CEO is confident AI rally will continue

17.10.2026 03:37

"Musk Magic" Is Back: CFRA Analyst Raises Tesla's Price Target Due to the Flying Car

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026